• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Lipid Management to Reduce ASCVD Risk: What Would AHA/ACC Do?


Try these 5 questions on patient CVD risk scenarios likely to present to primary care. Find out what you know about AHA/ACC guideline-recommended strategies.

Assessment of risk for athersclerotic cardiovascular disease (ASCVD) is the foundation of preventive cardiology and is a component of comprehensive primary care.

In 2019 the American Heart Association and American College of Cardiology published an updated Guideline on the Primary Prevention of Cardiovascular Disease. When to commence assessment, factors to consider when deciding to initiate drug therapy, when to include "risk enhancers" in a decision on therapy, what to do when coronary artery calcium score = 0--these are only the most basic elements of guidance in the document.

The 5 questions that follow touch on these points and and test what you know about assessing and managing ASCVD risk in primay care.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.